⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628925 | 0.81 | — | — | |
| SCHEMBL26709417 | 0.77 | — | — | |
| SCHEMBL25077812 | 0.77 | — | — | |
| SCHEMBL15744017 | 0.77 | — | — | |
| SCHEMBL567538 | 0.77 | LMNA (0.33) | — | |
| SCHEMBL27828613 | 0.77 | CDK2 (0.39) | — | |
| Hydrochloric Acid SCHEMBL26613899 | 0.76 | CCNE1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL26613904 | 0.76 | CCNE1 (0.30) | — | |
| SCHEMBL20780325 | 0.76 | CCNE1 (0.37) | — | |
| SCHEMBL19507920 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-10-27 | — | — | US | disclosed |
| US-11447460-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-09-20 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| CN-1980904-A | CETP inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |